Isolated Low HDL

作者: Robert S. Rosenson

DOI: 10.1007/978-1-60327-502-6_9

关键词: High-density lipoproteinRandomized controlled trialTherapeutic Lifestyle ChangesNiacinDyslipidemiaInternal medicineClinical trialMedicineStatinHypoalphalipoproteinemia

摘要: Primary hypoalphalipoproteinemia is characterized by isolated low levels of high-density lipoprotein cholesterol (HDL-C) below the tenth percentile compared with age- and gender-matched controls. Low HDL-C are associated an increased risk coronary heart disease (CHD) in epidemiologic studies, randomized clinical trials statin therapy identified patients at cardiovascular events, even when low-density (LDL-C) less than 70 mg/dL. Raising therapeutic lifestyle changes pharmacologic intervention might afford opportunities to further reduce CHD beyond LDL-C lowering. Statins first-line pharmacotherapy for treatment dyslipidemia events statins can also improve levels, although extent which they modify varies. Combining niacin raises more a alone this combination has been shown atherosclerosis two small-scale trials. One large-scale trial initiated investigate efficacy statin–niacin monotherapy.

参考文章(43)
Rakesh S. Birjmohun, Barbara A. Hutten, John J.P. Kastelein, Erik S.G. Stroes, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. Journal of the American College of Cardiology. ,vol. 45, pp. 185- 197 ,(2005) , 10.1016/J.JACC.2004.10.031
Martin I Freed, Robert Ratner, Santica M Marcovina, Margaret M Kreider, Nandita Biswas, Beth R Cohen, John D Brunzell, Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. American Journal of Cardiology. ,vol. 90, pp. 947- 952 ,(2002) , 10.1016/S0002-9149(02)02659-0
B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M.-R. Taskinen, L. Groop, Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome Diabetes Care. ,vol. 24, pp. 683- 689 ,(2001) , 10.2337/DIACARE.24.4.683
James D Otvos, Elias J Jeyarajah, William C Cromwell, Measurement issues related to lipoprotein heterogeneity. American Journal of Cardiology. ,vol. 90, pp. 22- 29 ,(2002) , 10.1016/S0002-9149(02)02632-2
Robert S. Rosenson, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Boaz Hirshberg, James C. Stolzenbach, Laura A. Williams, Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus Cardiovascular Drugs and Therapy. ,vol. 25, pp. 47- 57 ,(2011) , 10.1007/S10557-010-6273-5
Terje R. Pedersen, Anders G. Olsson, Ole Færgeman, John Kjekshus, Hans Wedel, Kåre Berg, Lars Wilhelmsen, Torben Haghfelt, Gudmundur Thorgeirsson, Kalevi Pyörälä, Tatu Miettinen, Bjørn Christophersen, Jonathan A. Tobert, Thomas A. Musliner, Thomas J. Cook, Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S) Circulation. ,vol. 97, pp. 1453- 1460 ,(1998) , 10.1161/01.CIR.97.15.1453
Fredrik Karpe, Keith N Frayn, The nicotinic acid receptor--a new mechanism for an old drug. The Lancet. ,vol. 363, pp. 1892- 1894 ,(2004) , 10.1016/S0140-6736(04)16359-9
Anne Goldberg, Peter Alagona, David M Capuzzi, John Guyton, John M Morgan, John Rodgers, Richard Sachson, Paul Samuel, Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia American Journal of Cardiology. ,vol. 85, pp. 1100- 1105 ,(2000) , 10.1016/S0002-9149(00)00703-7